Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
about
How I treat acquired aplastic anemiaCurrent concepts in the pathophysiology and treatment of aplastic anemiaPathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromesThe role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failureHorse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia.Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia.Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapyDiagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC)Predicting response to immunosuppressive therapy in childhood aplastic anemia.Severe fatigue: could it be aplastic anemia?Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China.Clinical management of aplastic anemia.Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors.Immunosuppressive therapy in patients with aplastic anemia: a single-center retrospective study.Impaired Autophagy in Adult Bone Marrow CD34+ Cells of Patients with Aplastic Anemia: Possible Pathogenic Significance.Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.Thymoma followed by aplastic anemia - two different responses to immunosuppressive therapyParoxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine.Anemia of Central Origin.Horse versus rabbit antithymocyte globulin in acquired aplastic anemiaTreatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized studyHematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience.High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in severe aplastic anemia patients: A cohort study.
P2860
Q24617687-4D568540-E4A6-4674-82FC-D38930D99CD2Q24685812-4090B617-40B9-4F2E-9E7D-4119000E09B8Q26863182-809A331F-C069-46CB-8E74-D8D4CD187772Q33608711-0851260A-45C5-41BF-920A-BC01F6A1C8A6Q33757965-98430763-1928-48AF-B5A1-24D454312957Q33978891-9EA52A6C-1EA9-4C5A-BC66-9030E8464291Q34172212-9390E36F-B8C9-43A7-9F95-97756ECBD73FQ34431435-F1D29748-8D2E-495D-A3C3-FF07B4660752Q34555435-67A68B5A-B9C5-4457-961E-41A39BE7F85EQ34649082-B00DD299-C509-47CA-B289-A2CECDBC660DQ34790303-7ECC888A-93DD-4D02-99FC-A2B409C9E6D4Q34890595-A250F548-E2CA-482E-8DE0-5B8E17D5B235Q34989207-3D7FC6C1-842D-4821-9EC7-179CFA25E8E0Q35019920-E234E1BC-1811-4531-AA6E-56EC8B442B38Q35088529-EF7FB33C-DE0E-46B1-9804-2489AE0EF323Q35112372-EDFABDF7-F21D-453D-95A1-5AD4F9B8D1CAQ35220764-92AA8AF0-C819-460E-8309-D5926829F44CQ35258960-6B795659-9665-4025-9B11-4331C6CFFD23Q35602992-86E4837E-EC48-4D6A-89A4-59E51FE5E36EQ35941441-F9404424-AEEF-41D2-ADA4-EF3AC2FEC906Q35967925-1A986CA6-5EE7-4EC5-A73F-21F05B4D95BEQ36283101-BAD8CCAA-C133-4004-9BC2-E95F8D763ACFQ36337581-59079A26-9661-4EA4-B714-88FBA266B59EQ36514033-C1A5C9AF-9149-4E6F-9F5E-1244E4B136D0Q36779735-557E9D1F-38E3-4124-9AF1-3CFD8EB0603DQ36784115-9807BE32-BEB9-42F5-81A0-274A41E3463BQ37040881-56A35F64-A598-40E7-9BBB-F0407ADA79DBQ37112911-4F360051-4F7E-4D1B-A369-E75D3A54403BQ37428425-7F830F6F-3701-467B-8C18-538487CEB0E7Q37676274-59AC22E3-73BE-48A9-85DD-1820F9A9E385Q37677193-C1B8F528-04CF-4E96-99DB-E68B62A46C30Q38636146-4E8D840E-2100-401F-90CD-1BC76E00F7A7Q40496183-5963892E-4028-48A1-AD3A-2D0F32DF0463Q50053950-9433370D-084C-4B07-8A1C-C046484D177F
P2860
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@en
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@nl
type
label
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@en
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@nl
prefLabel
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@en
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@nl
P2093
P1433
P1476
Immunosuppressive therapy usin ...... with acquired aplastic anemia.
@en
P2093
Mugishima H
Tsuchida M
Tsukimoto I
Yamamoto M
P304
P407
P577
2000-09-01T00:00:00Z